Myasthenia Gravis: A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)Myasthenia Gravis, Autoimmune, Experimental: Any autoimmune animal disease model used in the study of MYASTHENIA GRAVIS. Injection with purified neuromuscular junction acetylcholine receptor (AChR) (see RECEPTORS, CHOLINERGIC) components results in a myasthenic syndrome that has acute and chronic phases. The motor endplate pathology, loss of acetylcholine receptors, presence of circulating anti-AChR antibodies, and electrophysiologic changes make this condition virtually identical to human myasthenia gravis. Passive transfer of AChR antibodies or lymphocytes from afflicted animals to normals induces passive transfer experimental autoimmune myasthenia gravis. (From Joynt, Clinical Neurology, 1997, Ch 54, p3)Thymectomy: Surgical removal of the thymus gland. (Dorland, 28th ed)Receptors, Cholinergic: Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology.Thymoma: A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)Pyridostigmine Bromide: A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.Thymus Neoplasms: Tumors or cancer of the THYMUS GLAND.Thymus Hyperplasia: Enlargement of the thymus. A condition described in the late 1940's and 1950's as pathological thymic hypertrophy was status thymolymphaticus and was treated with radiotherapy. Unnecessary removal of the thymus was also practiced. It later became apparent that the thymus undergoes normal physiological hypertrophy, reaching a maximum at puberty and involuting thereafter. The concept of status thymolymphaticus has been abandoned. Thymus hyperplasia is present in two thirds of all patients with myasthenia gravis. (From Segen, Dictionary of Modern Medicine, 1992; Cecil Textbook of Medicine, 19th ed, p1486)Myasthenia Gravis, Neonatal: A disorder of neuromuscular transmission that occurs in a minority of newborns born to women with myasthenia gravis. Clinical features are usually present at birth or develop in the first 3 days of life and consist of hypotonia and impaired respiratory, suck, and swallowing abilities. This condition is associated with the passive transfer of acetylcholine receptor antibodies through the placenta. In the majority of infants the myasthenic weakness resolves (i.e., transient neonatal myasthenia gravis) although this disorder may rarely continue beyond the neonatal period (i.e., persistent neonatal myasthenia gravis). (From Menkes, Textbook of Child Neurology, 5th ed, p823; Neurology 1997 Jan;48(1):50-4)Autoantibodies: Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.Blepharoptosis: Drooping of the upper lid due to deficient development or paralysis of the levator palpebrae muscle.Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.Cholinesterase Inhibitors: Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.Plasmapheresis: Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use.Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.Torpedo: A genus of the Torpedinidae family consisting of several species. Members of this family have powerful electric organs and are commonly called electric rays.Neuromuscular Junction: The synapse between a neuron and a muscle.Diplopia: A visual symptom in which a single object is perceived by the visual cortex as two objects rather than one. Disorders associated with this condition include REFRACTIVE ERRORS; STRABISMUS; OCULOMOTOR NERVE DISEASES; TROCHLEAR NERVE DISEASES; ABDUCENS NERVE DISEASES; and diseases of the BRAIN STEM and OCCIPITAL LOBE.Thymus Gland: A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.Rats, Inbred LewAutoimmune Diseases: Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.Receptors, Nicotinic: One of the two major classes of cholinergic receptors. Nicotinic receptors were originally distinguished by their preference for NICOTINE over MUSCARINE. They are generally divided into muscle-type and neuronal-type (previously ganglionic) based on pharmacology, and subunit composition of the receptors.Ocular Motility Disorders: Disorders that feature impairment of eye movements as a primary manifestation of disease. These conditions may be divided into infranuclear, nuclear, and supranuclear disorders. Diseases of the eye muscles or oculomotor cranial nerves (III, IV, and VI) are considered infranuclear. Nuclear disorders are caused by disease of the oculomotor, trochlear, or abducens nuclei in the BRAIN STEM. Supranuclear disorders are produced by dysfunction of higher order sensory and motor systems that control eye movements, including neural networks in the CEREBRAL CORTEX; BASAL GANGLIA; CEREBELLUM; and BRAIN STEM. Ocular torticollis refers to a head tilt that is caused by an ocular misalignment. Opsoclonus refers to rapid, conjugate oscillations of the eyes in multiple directions, which may occur as a parainfectious or paraneoplastic condition (e.g., OPSOCLONUS-MYOCLONUS SYNDROME). (Adams et al., Principles of Neurology, 6th ed, p240)Eye Manifestations: Ocular disorders attendant upon non-ocular disease or injury.Ophthalmoplegia: Paralysis of one or more of the ocular muscles due to disorders of the eye muscles, neuromuscular junction, supporting soft tissue, tendons, or innervation to the muscles.Electromyography: Recording of the changes in electric potential of muscle by means of surface or needle electrodes.Lambert-Eaton Myasthenic Syndrome: An autoimmune disease characterized by weakness and fatigability of proximal muscles, particularly of the pelvic girdle, lower extremities, trunk, and shoulder girdle. There is relative sparing of extraocular and bulbar muscles. CARCINOMA, SMALL CELL of the lung is a frequently associated condition, although other malignancies and autoimmune diseases may be associated. Muscular weakness results from impaired impulse transmission at the NEUROMUSCULAR JUNCTION. Presynaptic calcium channel dysfunction leads to a reduced amount of acetylcholine being released in response to stimulation of the nerve. (From Adams et al., Principles of Neurology, 6th ed, pp 1471)Motor Endplate: The specialized postsynaptic region of a muscle cell. The motor endplate is immediately across the synaptic cleft from the presynaptic axon terminal. Among its anatomical specializations are junctional folds which harbor a high density of cholinergic receptors.Muscles: Contractile tissue that produces movement in animals.Bungarotoxins: Neurotoxic proteins from the venom of the banded or Formosan krait (Bungarus multicinctus, an elapid snake). alpha-Bungarotoxin blocks nicotinic acetylcholine receptors and has been used to isolate and study them; beta- and gamma-bungarotoxins act presynaptically causing acetylcholine release and depletion. Both alpha and beta forms have been characterized, the alpha being similar to the large, long or Type II neurotoxins from other elapid venoms.Antibodies: Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)Muscle Weakness: A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)Electrophorus: A genus of fish, in the family GYMNOTIFORMES, capable of producing an electric shock that immobilizes fish and other prey. The species Electrophorus electricus is also known as the electric eel, though it is not a true eel.Neuromuscular Junction Diseases: Conditions characterized by impaired transmission of impulses at the NEUROMUSCULAR JUNCTION. This may result from disorders that affect receptor function, pre- or postsynaptic membrane function, or ACETYLCHOLINESTERASE activity. The majority of diseases in this category are associated with autoimmune, toxic, or inherited conditions.Oculomotor Muscles: The muscles that move the eye. Included in this group are the medial rectus, lateral rectus, superior rectus, inferior rectus, inferior oblique, superior oblique, musculus orbitalis, and levator palpebrae superioris.Plasma Exchange: Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)Antibodies, Antinuclear: Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.Muscle, Skeletal: A subtype of striated muscle, attached by TENDONS to the SKELETON. Skeletal muscles are innervated and their movement can be consciously controlled. They are also called voluntary muscles.Ventilators, Mechanical: Mechanical devices used to produce or assist pulmonary ventilation.Neurology: A medical specialty concerned with the study of the structures, functions, and diseases of the nervous system.Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.Bed Conversion: The reallocation of beds from one type of care service to another, as in converting acute care beds to long term care beds.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Mycophenolic Acid: An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Cardiovascular Deconditioning: A change in cardiovascular function resulting in a reduction in BLOOD VOLUME, and reflex DIURESIS. It occurs frequently after actual or simulated WEIGHTLESSNESS.Physical Fitness: The ability to carry out daily tasks and perform physical activities in a highly functional state, often as a result of physical conditioning.

TE671 cell-based ELISA for anti-acetylcholine receptor antibody determination in myasthenia gravis. (1/830)

BACKGROUND: Acetylcholine receptor (AChR) from human muscles is the antigen used currently in radioimmunoprecipitation assays (RIPAs) for the determination of anti-AChR antibodies in the diagnosis of myasthenia gravis (MG). Our aim was to develop and validate an ELISA using TE671 cells as the source of AChR. METHODS: After TE671 cell homogenization, the crude AChR extract was used for plate coating. Anti-AChR antibodies were determined in 207 MG patients and in 77 controls. RESULTS: The mean intra- and interassay CVs (for two samples with different anti-AChR antibody concentrations) were 9.7% and 15.7%, respectively. Test sensitivity and specificity, for generalized MG, were 79.5% (95% confidence interval, 72.8-85.0%) and 96.1% (89.0-99.1%). The detection limit was 2 nmol/L. Anti-AChR antibody concentrations from 53 MG patients, as tested with our ELISA, showed good agreement with an RIPA with a mean difference (SD) of 1.0 (5.6) nmol/L. CONCLUSION: Our ELISA is a simple screening test for the diagnosis of MG and enables rapid and inexpensive patient follow-up.  (+info)

Myasthenia gravis and polymyositis as manifestations of chronic graft-versus-host-disease. (2/830)

Myasthenia gravis and polymyositis are each a rare manifestation of immune dysregulation in chronic graft-versus-host disease (cGVHD). We report a 4-year-old boy with idiopathic acquired aplastic anemia who developed myasthenia gravis 22 months and polymyositis 69 months after an allogeneic BMT (5/6 matched, MLC-nonreactive). The occurrence of both syndromes in one patient is unique. Autoimmune dysfunction may be associated with the development of cGVHD as demonstrated by the high incidence of prior aplastic anemia in BMT patients presenting with myasthenia gravis and polymyositis. Recognition of these neurologic manifestations is important in the diagnosis and treatment of cGVHD.  (+info)

Experimental autoimmune myasthenia gravis and CD5+ B-lymphocyte expression. (3/830)

Myasthenia gravis is one of the typical organ specific autoimmune disease and the CD5+ B-lymphocytes are known to be associated with the secretion of autoimmune antibodies. The authors performed the study to establish an animal model of experimental autoimmune myasthenia gravis (EAMG) by immunizing the nicotinic acetylcholine receptor (AChR) and to understand CD5+ B-lymphocyte changes in peripheral blood of EAMGs. Lewis rats weighing 150-200 g were injected subcutaneously three times with 50 microg AChR purified from the electric organ of Torpedo marmorata and Freund's adjuvant. The EAMG induction was assessed by evaluating clinical manifestations. The CD5+ B-lymphocyte was double stained using monoclonal PE conjugated anti-CD5+ and FITC conjugated anti-rat CD45R antibodies and calculated using a fluorescence-activated cell sorter (FACS). In three out of ten Lewis rats injected with purified AChR, the EAMG models were established. The animals showed definite clinical weakness responded to neostigmine; they had difficulty in climbing the slope, or easily fell down from a vertical cage. The range of CD5+ B-lymphocytes of peripheral blood in the EAMG models was 10.2%-17.5%, which was higher than in controls. In conclusion, the EAMG models were successfully established and the CD5+ B-lymphocyte expression in peripheral blood increased in EAMGs. This provided indirect evidence of the autoimmune pathomechanism of human myasthenia gravis.  (+info)

Congenital myasthenia gravis: clinical and HLA studies in two brothers. (4/830)

Two brothers with congenital myasthenia gravis are described. In both, ptosis and ophthalmoplegia responded poorly to oral anticholinesterase therapy and to thymectomy. The brothers had two different HLA haplotypes and neither had the HLA-A1-B8-DW3 haplotypes which are commonly associated with myathenia gravis in adult-onset cases.  (+info)

The value of thymectomy in myasthenia gravis: a computer-assisted matched study. (5/830)

In the absence of a prospective randomized study of patients treated conservatively or with thymectomy, a computer-assisted retrospective matches study was devised. Of 563 patients treated for myasthenia gravis without thymoma up to 1965, 104 had thymectomy. With computer assistance, each surgical patient was matched with a medical patient on the basis of age, sex, and severity and duration of disease. On this basis 80 of the 104 surgical patients could be matched satisfactorily. There were 16 males and 64 females in each of the matched surgically treated and medical control groups. A complete remission was experienced by 27 of the 78 patients in the surgical group as compared to 6 of the medical group. Improvement was noted by 26 of 78 surgically treated patients and 13 of 78 receiving medical treatment. Survival for patients having thymectomy. Thirty-four patients in the medical group had died as compared to 11 in the surgical group. Comparison of survival in relation to sex, duration of symptoms, or age (less than 30 or less than 30 years) did not show a significant difference. Until more effective treatment is available for myasthenia gravis, thymectomy deserves consideration for both sexes, and with increased age or long duration of symptoms.  (+info)

Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. (6/830)

IFN-gamma can either adversely or beneficially affect certain experimental autoimmune diseases. To study the role of IFN-gamma in the autoantibody-mediated experimental autoimmune myasthenia gravis (EAMG), an animal model of myasthenia gravis in humans, IFN-gammaR-deficient (IFN-gammaR-/-) mutant C57BL/6 mice and congenic wild-type mice were immunized with Torpedo acetylcholine receptor (AChR) plus CFA. IFN-gammaR-/- mice exhibited significantly lower incidence and severity of muscle weakness, lower anti-AChR IgG Ab levels, and lower Ab affinity to AChR compared with wild-type mice. Passive transfer of serum from IFN-gammaR-/- mice induced less muscular weakness compared with serum from wild-type mice. In contrast, numbers of lymph node cells secreting IFN-gamma and of those expressing IFN-gamma mRNA were strongly augmented in the IFN-gammaR-/- mice, reflecting a failure of negative feedback circuits. Cytokine studies by in situ hybridization revealed lower levels of lymphoid cells expressing AChR-reactive IL-1beta and TNF-alpha mRNA in AChR + CFA-immunized IFN-gammaR-/- mice compared with wild-type mice. No differences were found for AChR-reactive cells expressing IL-4, IL-10, or TGF-beta mRNA. These results indicate that IFN-gamma promotes systemic humoral responses in EAMG by up-regulating the production and the affinity of anti-AChR autoantibodies, thereby contributing to susceptibility to EAMG in C57BL/6-type mice.  (+info)

Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor. (7/830)

A recurring epitope in the human acetylcholine receptor (AChR) alpha subunit (alpha146-160) is presented to specific T cells from myasthenia gravis patients by HLA-DRB3*0101-"DR52a"-or by DR4. Here we first map residues critical for DR52a in this epitope by serial Ala substitution. For two somewhat similar T cells, this confirms the recently deduced importance of hydrophobic "anchor" residues at peptide p1 and p9; also of Asp at p4, which complements this allele's distinctive Arg74 in DRbeta. Surprisingly, despite the 9 sequence differences in DRbeta between DR52a and DR3, merely reducing the bulk of the peptide's p1 anchor residue (Trp149-->Phe) allowed maximal cross-presentation to both T cells by DR3 (which has Val86 instead of Gly). The shared K71G73R74N77 motif in the alpha helices of DR52a and DR3 thus outweighs the five differences in the floor of the peptide-binding groove. A second issue is that T cells selected in vitro with synthetic AChR peptides rarely respond to longer Ag preparations, whereas those raised with recombinant subunits consistently recognize epitopes processed naturally even from whole AChR. Here we compared one T cell of each kind, which both respond to many overlapping alpha140-160 region peptides (in proliferation assays). Even though both use Vbeta2 to recognize peptides bound to the same HLA-DR52a in the same register, the peptide-selected line nevertheless proved to depend on a recurring synthetic artifact-a widely underestimated problem. Unlike these contaminant-responsive T cells, those that are truly specific for natural AChR epitopes appear less heterogeneous and therefore more suitable targets for selective immunotherapy.  (+info)

Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients. (8/830)

The nicotinic acetylcholine receptor (AChR) is the autoantigen in the human autoimmune disease myasthenia gravis (MG). Anti-AChR antibodies in MG sera bind mainly to conformational epitopes, therefore the determination of their specificities requires the use of native AChR. Antibody competition studies suggest that most MG antibodies are directed against the extracellular part of the molecule, whereas antibodies directed against the cytoplasmic region of the AChR have not been detected. To determine whether even small quantities of such antibodies exist in MG sera, we performed competition experiments based on the inhibition by MG sera of the binding of MoAbs to the human AChR, rather than inhibition by MoAbs of the binding of MG sera performed earlier. When MoAbs directed against cytoplasmic epitopes on the alpha or beta subunits (alpha 373-380 and beta 354-360) were used as test MoAbs, 17% or 9% of MG sera inhibited the binding of the anti-alpha or anti-beta subunit MoAbs, respectively, by > or = 50%. Non-specific inhibition was excluded. These results suggest the presence, in several MG sera, of antibodies directed against cytoplasmic regions of the AChR; yet these antibodies seemed to represent a relatively small proportion of the total anti-AChR antibodies. The corresponding epitopes may be involved in the inducing mechanisms in certain MG cases, and knowledge of the presence of such antibodies may be useful in understanding the autoimmune mechanism involved in MG.  (+info)

  • Our results support the idea that thymectomy is a valid treatment option for a major form of myasthenia gravis," said Gil Wolfe, M.D., Professor and Irvin and Rosemary Smith Chair of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, and a leader of the study. (enewspf.com)
  • The study draws from the county-based prospective myasthenia gravis register implemented by the Neurology Department at Hospital General de Vic in 1991. (elsevier.es)
  • In our ongoing series this month, June being Generalized Myasthenia Gravis Awareness Month, we are joined this afternoon with Dr. Tahseen Mozaffar, Vice Chair of Education and Professor Department of Neurology at the University of California joining us today to further educate us about this rare neuromuscular disease. (healthprofessionalradio.com.au)
  • At Integrated Neurology Services, we provide extensive treatment options to help patients with Myasthenia gravis get the care they need and deserve. (integratedneurologyservices.com)
  • Until this study, the only evidence was from non-randomized studies that contained significant bias issues," said Wolfe, an expert on neuromuscular disorders with a special focus on MG, who was awarded the 2015 Doctor of the Year award from the Myasthenia Gravis Foundation of America. (buffalo.edu)
  • Introduction: The aim of this study was to elucidate the effectiveness of oral prednisolone (PSL) according to dosing regimen in 472 patients with myasthenia gravis (MG). Methods: We compared the clinical characteristics and PSL treatment between 226 patients who achieved minimal manifestations (MM) or better and 246 patients who remained improved (I) or worsened, according to the MG Foundation of America postintervention status. (elsevier.com)
  • In some severe cases of Myasthenia Gravis, dogs may be hospitalized until they are stabilized with Anti-acetylcholinesterase medications. (simplewag.com)
  • Mei's lab found a link between agrin and LRP4 in 2008, reported LRP4 antibodies as a new cause of myasthenia gravis in 2013 and that agrin antibodies were associated with the disease the next year. (eurekalert.org)
  • I shopped online for a cane to help me deal with the double vision and altered depth perception that I experience as a symptom of Myasthenia Gravis (MG). I was thrilled to find a metallic purple one. (jeriaielloart.com)
  • This is a study that the myasthenia gravis community has needed for a long time," said Robin Conwit, M.D., program director, at NIH's National Institute of Neurological Disorders and Stroke (NINDS). (enewspf.com)
  • The increasing demand on diagnostic assays that are sensitive and specific for pathogenic antibodies, and the interest in identifying new antigens, prompted the development of cell-based assays for the detection of autoantibodies in myasthenia gravis and other autoimmune disorders. (ox.ac.uk)
  • Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. (medications.com)
  • Myasthenia gravis is an autoimmune condition distinguished by the fast-weakening and fatigue of voluntary muscles and muscle groups . (steadyhealth.com)
  • While MS attacks the central nervous system (CNS) and depletes the protective myelin coating and exposes the nerves to damage, Myasthenia gravis causes communication issues in the peripheral nervous system, with its effects seen at the connection sites on the muscles that receive signals. (steadyhealth.com)
  • The muscles around the eyes are particularly likely to be affected by myasthenia gravis, and eye problems are the first sign of the disease in about 40% of cases. (safein4.com)
  • Transitory (neonatal) myasthenia in new-born babies should be separated from the familial cases. (nih.gov)
  • Your vet may choose to test for myasthenia gravis by injecting your dog with edrophonium chloride. (vetinfo.com)
  • There are two common types of myasthenia gravis. (vetinfo.com)
  • As we briefly mentioned above, there are two main types of myasthenia gravis in dogs: acquired and congenital. (simplewag.com)
  • The specific causes of Myasthenia Gravis in dogs have been researched by professional veterinarians for years. (simplewag.com)
  • Generalized fatigue in myasthenia gravis results in physical deconditioning that reduces fitness and increases risk of obesity, hypertension, elevated cholesterol and type 2 diabetes. (clinicaltrials.gov)
  • Generalized fatigue in myasthenia gravis results in a sedentary lifestyle and profound physical deconditioning, leading to reduced fitness and increased risk of obesity, hypertension, dyslipidemia, and type 2 diabetes. (clinicaltrials.gov)
  • Hypotheses are that a) subjects with myasthenia gravis are physically inactive with reduced fitness level and high incidence of obesity and poor cardiovascular disease risk profile, and b) a 3 month multi-modal home exercise program that includes aerobic, resistive, and pulmonary training components will improve physical activity, strength, fitness, dyspnea, body composition and reduce cardiovascular disease risk. (clinicaltrials.gov)
  • A Cochrane review 1 included one study with a total of 10 subjects with myasthenia gravis (MG). It used acetylcholinesterase inhibitor, intranasal neostigmine, including 3 participants with ocular and 7 with generalised myasthenia gravis. (unboundmedicine.com)
  • Scientists are evaluating new and improving current treatments for myasthenia gravis. (abingtonneurology.com)
  • Still, the cause of the disease remained a mystery until 1960, when Simpson proposed that myasthenia gravis was caused by antibodies against the acetylcholine receptor. (yale.edu)
13th International Conference on Myasthenia Gravis | The New York Academy of Sciences
13th International Conference on Myasthenia Gravis | The New York Academy of Sciences (nyas.org)
Myasthenia Gravis | St. Louis Children's Hospital
Myasthenia Gravis | St. Louis Children's Hospital (stlouischildrens.org)
Myasthenia Gravis
Myasthenia Gravis (els.net)
Myasthenia Gravis: Frequently Asked Questions
Myasthenia Gravis: Frequently Asked Questions (myasthenia.org)
Study examines impact of 2 new antibodies in causing, treating myasthenia gravis | EurekAlert! Science News
Study examines impact of 2 new antibodies in causing, treating myasthenia gravis | EurekAlert! Science News (eurekalert.org)
Survivin as a Potential Mediator to Support Autoreactive Cell Survival in Myasthenia Gravis: A Human and Animal Model Study
Survivin as a Potential Mediator to Support Autoreactive Cell Survival in Myasthenia Gravis: A Human and Animal Model Study (journals.plos.org)
12 scary things your eyes say about your health
12 scary things your eyes say about your health (cbsnews.com)
Pictures: Reasons You're Short of Breath
Pictures: Reasons You're Short of Breath (webmd.com)
Head feels heavy: 5 causes, symptoms, and treatments
Head feels heavy: 5 causes, symptoms, and treatments (medicalnewstoday.com)
12 Myasthenia Gravis Symptoms, Causes, Treatments & Cure
12 Myasthenia Gravis Symptoms, Causes, Treatments & Cure (rxlist.com)
Methylprednisolone Sodium Succinate Monograph for Professionals - Drugs.com
Methylprednisolone Sodium Succinate Monograph for Professionals - Drugs.com (drugs.com)
Pediatric Thymoma: Background, Pathophysiology, Epidemiology
Pediatric Thymoma: Background, Pathophysiology, Epidemiology (emedicine.medscape.com)
Detrol LA (Tolterodine Tartrate): Uses, Dosage, Side Effects, Interactions, Warning
Detrol LA (Tolterodine Tartrate): Uses, Dosage, Side Effects, Interactions, Warning (rxlist.com)
Dexamethasone sodium phosphate Monograph for Professionals - Drugs.com
Dexamethasone sodium phosphate Monograph for Professionals - Drugs.com (drugs.com)
Moebius Syndrome: Differential Diagnosis
Moebius Syndrome: Differential Diagnosis (news-medical.net)
Hydrocortisone Sodium Succinate Monograph for Professionals - Drugs.com
Hydrocortisone Sodium Succinate Monograph for Professionals - Drugs.com (drugs.com)
Electromyography (EMG) Laboratory - Massachusetts General Hospital, Boston, MA
Electromyography (EMG) Laboratory - Massachusetts General Hospital, Boston, MA (massgeneral.org)
Neurocritical Care and Emergency Neurology - Massachusetts General Hospital, Boston, MA
Neurocritical Care and Emergency Neurology - Massachusetts General Hospital, Boston, MA (massgeneral.org)
Toviaz (Fesoterodine Fumarate Extended-Release Tablets): Side Effects, Interactions, Warning, Dosage & Uses
Toviaz (Fesoterodine Fumarate Extended-Release Tablets): Side Effects, Interactions, Warning, Dosage & Uses (rxlist.com)
MyMg on the App Store
MyMg on the App Store (itunes.apple.com)
Proquin XR (Ciprofloxacin Hcl): Side Effects, Interactions, Warning, Dosage & Uses
Proquin XR (Ciprofloxacin Hcl): Side Effects, Interactions, Warning, Dosage & Uses (rxlist.com)
Clinical Trials | Day Lab | Stanford Medicine
Clinical Trials | Day Lab | Stanford Medicine (med.stanford.edu)
Fatigue in patients with myasthenia gravis | SpringerLink
Fatigue in patients with myasthenia gravis | SpringerLink (link.springer.com)
Floxin Tablets - FDA prescribing information, side effects and uses
Floxin Tablets - FDA prescribing information, side effects and uses (drugs.com)
Floxin (Ofloxacin): Side Effects, Interactions, Warning, Dosage & Uses
Floxin (Ofloxacin): Side Effects, Interactions, Warning, Dosage & Uses (rxlist.com)
Zithromax (Azithromycin): Side Effects, Interactions, Warning, Dosage & Uses
Zithromax (Azithromycin): Side Effects, Interactions, Warning, Dosage & Uses (rxlist.com)
Search of: Recruiting, Not yet recruiting, Available Studies | 'Myasthenia Gravis' - Modify Search - ClinicalTrials.gov
Search of: Recruiting, Not yet recruiting, Available Studies | 'Myasthenia Gravis' - Modify Search - ClinicalTrials.gov (clinicaltrials.gov)
New Medical Therapies Trial Results in Myasthenia Gravis (Chronic Weakness) | CenterWatch
New Medical Therapies Trial Results in Myasthenia Gravis (Chronic Weakness) | CenterWatch (centerwatch.com)
Levaquin (Levofloxacin): Side Effects, Interactions, Warning, Dosage & Uses
Levaquin (Levofloxacin): Side Effects, Interactions, Warning, Dosage & Uses (rxlist.com)
Globus Sensation. Myasthenia gravis and globus information | Patient
Globus Sensation. Myasthenia gravis and globus information | Patient (patient.info)
Researcher Says Immune Cells Cluster and Communicate 'Like Bees'
Researcher Says Immune Cells Cluster and Communicate 'Like Bees' (medindia.net)
New Way to Increase the Immunity of the Immune System
New Way to Increase the Immunity of the Immune System (medindia.net)
Immune Responses to Flu Shots can be Predicted by Quick Test
Immune Responses to Flu Shots can be Predicted by Quick Test (medindia.net)
New Treatment for Cancer Lies in Activating Key Immune Cells
New Treatment for Cancer Lies in Activating Key Immune Cells (medindia.net)
Tumors Use Sugar to Disable Immune Cells
Tumors Use Sugar to Disable Immune Cells (medindia.net)